

ERICA Consortium:


The ERICA consortium consists of 29 partners, amongst which all 24 [European Reference Networks](#) (ERNs), EURORDIS, EJP RD, Orphanet, Mapi Trust Research, and EATRIS. ERICA is coordinated by Alberto Pereira (Endo-ERN coordinator, Leiden University Medical Center, the Netherlands).

The project runs from 1st March 2021 – 28th February 2025.

Main objectives:


- to record, coordinate, and disseminate ERN research activities in line with the CSA’s strategic positioning;
- to facilitate collection, sharing, and analysis of research data within and between ERNs;
- to advance patient-centered research and outcomes monitoring by promoting the identification and application of patient-centered outcome measures for rare diseases;
- to map, integrate and link ongoing activities with regards to facilitating international clinical trials;
- to encourage methodology sharing and increase the innovation potential of ERNs.

Positioning of ERICA within the Rare Disease research ecosystem:






Work Packages



Executive Committee

Alberto Pereira	WP1, WP6, WP 7 leader
Franz Schaefer	WP2 leader
Eduardo Lopez Granados	WP2 leader
Mar Mañú Pereira	WP3 leader
Ana Rath	WP3 leader
Ralf-Dieter Hilgers	WP4 leader
Luca Sangiorgi	WP4 leader
Ruth Ladenstein	WP5 leader
Anton Ussi	WP5 leader
Maurizio Scarpa	WP6 leader

Organisational structure





Consortium Agreement

The DESCA Horizon 2020 model consortium agreement is used to manage the consortium, where beneficiaries have internal arrangements regarding their operation and coordination to ensure that the project is implemented properly.

Reporting

Periodic Reporting (every 18 months)


- Consolidated periodic technical report;
- Individual financial report of each partner;
- Reports to be submitted to the EC latest 60 days after the applicable period;
- After approval of the periodic report, the next pre-payments will be made.

The project is divided into 3 Periodic reporting periods:
- 1: month 1 (March 2021) to month 18 (August 2022)
- 2: month 19 (September 2022) to month 36 (February 2024)
- 3: month 37 (March 2024) to month 48 (February 2025)

Continuous Reporting (1st March 2021 – 28th February 2025)

- Reports on the progress of each individual milestone and deliverable to be provided timely by WP leads to ERICA coordinator, before due date of the specific milestone/deliverable;
- Reports will be submitted by ERICA coordinator to EC by uploading them to the EU Participant Portal;
- Each individual report will be reviewed by the EC and will be approved or rejected.

[The EU Participant Portal](#) is the tool for the project process overview and for the reporting to EU.



Dissemination & Communication

Each beneficiary must disseminate its results to the public and keep the coordinating office updated. The information must include all of the following:

- the terms "European Union (EU)" and "Horizon 2020";
- the *European Rare Disease Coordination and Support Action (acronym 'ERICA')*, grant nr 964908;
- the publication date, and length of embargo period if applicable, and
- a persistent identifier (either ERICA logo or reference to ERICA project with specific grant nr 964908).



[Quick guide and tools for Communication, Dissemination and Exploitation in Horizon 2020](#)

For communication and dissemination activities use the following text: *“This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 964908”.*


EU logo for H2020 projects

EU emblem



High-resolution emblems can be found here <http://europa.eu/about-eu/basic-information/symbols/flag/>

ERICA logo and PowerPoint template (Provided by the ERICA office)



ERICA website

The developed website www.ericard.eu will form a central platform to showcase all aspects of the project, including upcoming events and project publications. A stakeholder specific section will be created geared towards the EU member states, the pharmaceutical industry, patient representatives and individual patients. The website will be structured in such a way that data on a meta level can be shared with existing platforms.